Abstract The proposed use of a more precise standard for glycated (A 1c ) and non-glycated haemoglobin would lead to an A 1c value, when expressed as a percentage, that is lower than that currently in use. One approach advocated to address the potential confusion that would ensue is to replace 'HbA 1c ' with a new term, 'A 1c -derived average glucose.' We review evidence from several sources suggesting that A 1c is, in fact, inherently imprecise as a measure of average glucose, so that the proposed terminology should not be adopted.
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Moreover, because of educational efforts directed at the lay audience, 'A 1c ' is also emerging within the lexicon of our diabetic patients. An important debate is developing, however, regarding the manner in which A 1c should be measured in the management of patients with diabetes. The International Federation of Clinical Chemistry (IFCC) has proposed a new approach to A 1c , using a synthetic standard for glycated and non-glycated haemoglobin [1] . Existing normative ranges based on actual patient samples would be replaced with a more precise standard in which a specific chemical moiety representing a species of glycated A 1c is used, the substance fraction of the haemoglobin β-chain containing a stable hexose adduct on its N-terminal amino acid valine [2] . Comparison of assays using the standardisation methodology currently endorsed in the USA, Japan and Sweden with assays using the new approach suggests that the latter consistently generate lower A 1c levels [3] . The National Glycohemoglobin Standardization Program (NGSP) suggests that A 1c results be reported using these new more precise metrics, in IFCC units (as mmol A 1c /mol haemoglobin) [4] , which would give a range in non-diabetic persons of~25-42. Based on these results, derived NGSP units could also still be reported as the more familiar percentage, similar to that currently in use, giving a non-diabetic range of 2.5-4.2%. Of note, however, the introduction of an A 1c assay giving lower results in Sweden in the 1990s appeared to cause patients and clinicians to allow glycaemic control worsen [5] . This would certainly be undesirable, and so the use of the entirely new IFCC units, which do not overlap numerically with current A 1c percentages, appears reasonable.
The IFCC approach would, admittedly, cause significant confusion in the medical community. Two alternatives have been proposed. A 1c levels could simply be converted back to DCCT-like A 1c levels, which would have the advantage of continuity, but the conceptual disadvantage of providing a result that is factually incorrect. Another approach, suggested by a consensus committee representing the American Diabetes Association, the European Association for the Study of Diabetes, the International Federation of Clinical Chemistry and Laboratory Medicine and the International Diabetes Federation would be to abolish the term A 1c entirely, replacing it with a new name, the 'A 1c -derived average glucose' (ADAG). The purpose of the present essay is to summarise a number of recent lines of investigation suggesting that it may not be possible to predict true mean or average glucose with a high degree of accuracy in a given person based on his or her A 1c result.
The phenomenon of person-to-person variability in the degree of haemoglobin glycation has been described by a number of authors. The use of measures reflecting the difference between the measured A 1c and that predicted from home capillary glucose profiles has been employed in several studies. In one investigation of 128 type 1 diabetic children almost one-third showed a significant and clinically relevant difference between the two measures [6] . Others have analysed a publicly available DCCT database that includes 247,717 glucose measurements obtained by analysis of seven-point home capillary blood specimens with laboratory methods and approximately 72,000 accompanying A 1c values. One regression analysis indicated that the glucose profile explains just half of the variance in A 1c [7] . The authors of the analysis suggested that those persons with high haemoglobin glycation might be at increased risk of microvascular complications. An independent investigation supported this hypothesis by demonstrating that A 1c levels were higher in patients with type 1 diabetes who had developed retinopathy vs those who had not, after correction for fructosamine, another measure of mean glucose levels. This further suggested that glycation may have determinants other than prevailing glycaemia [8] . DCCT investigators have taken exception to aspects of this interpretation [9] , arguing with some reason that the seven-point capillary blood sample set might not be considered sufficiently representative of an entire 3 month period of glycaemia [10] . It is noteworthy, however, that another analysis using this same database showed that the conventional treatment group in the DCCT had consistently higher mean glucose concentrations than intensively treated patients at any given A 1c value, with a mean difference of 1.6 mmol/l (29 mg/dl) at an A 1c of 7%, increasing to 2.8 mmol/l (52 mg/dl) at an A 1c of 11% [11] . Furthermore, mean seven-point glucose (MPG), but not A 1c , predicted cardiovascular events during the DCCT study itself [12] , while it was not until a decade later, in the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up of the DCCT, that a difference between the intensive and conventional treatment groups in cardiovascular disease rates could be demonstrated [13] . The predictive power of the MPG appears to be strong biological evidence of the validity of the methodology. Notably, in a separate investigation, it was found that an individual whose MPG was 10 mmol/l (180 mg/dl) could have A 1c levels ranging from 6-11% [14] . One may independently observe this from examination of reports from the DCCT investigators themselves (Fig. 1) , which reveal that patients with an A 1c of 9% had mean plasma glucose ranging from~10-16.7 mmol/l (180-300 mg/dl) [15] . Taken together, these data suggest that the relationship between mean blood glucose and A 1c is not constant, differing depending on factors other than glycaemia. As a result, the concept of different diabetic individuals having different degrees of glycation for a given glucose level appears attractive [16] .
Certainly, it is well-recognised that a variety of haematological conditions, including persistent fetal haemoglobin, haemoglobin variants, the presence of carbamylated haemoglobin in uremic patients, and conditions with decreased erythrocyte survival, such as hemolysis, are associated with altered A 1c concentrations [17, 18] . Low A 1c levels are not uncommon in normal persons, and may be associated with haemoglobin S, C, or D, with various forms of anaemia, and with pregnancy, dyslipidemia, malignancy, cirrhosis, and acetylsalicylic acid use [19] . One therefore must presume that among persons with diabetes such conditions would be equally likely to lower A 1c below the level which might be Fig. 1 Relationship between A 1c and MPG, using capillary blood haemolysates collected before meals, 90 min after meals, and at bedtime, by DCCT participants in the home. Observe that patients with an A 1c of 9% had MPG ranging from~10-16.7 mmol/l (180-300 mg/dl) . Copyright © 2002 American Diabetes Association. From [15] . Reprinted with permission from The American Diabetes Association predicted from the actual average glycaemia. This is well recognized to occur during the third trimester of pregnancy in women with type 1 diabetes [20] , and there is evidence that diabetic persons with nephropathy have levels of A 1c differing from those would be predicted from the simultaneously measured serum fructosamine level [21] . Further studies are in progress of interrelationships between A 1c and erythrocyte survival, and between A 1c and the presence of renal and hepatic disease [22] . Interestingly, there is some evidence that high A 1c may itself be associated with reduced erythrocyte survival, so that A 1c might at high levels particularly underestimate the true degree of hyperglycaemia [23] , further implying need to closely examine factors affecting A 1c rather than assuming that it directly represents average glucose concentrations [24] .
A recent report of the relationship between A 1c (performed with the new IFCC assay) and mean glucose levels determined from continuous glucose monitoring (CGM) showed that at an A 1c of 7%, the mean glucose varied between 7.5 and 9 mmol/l (135 and 162 mg/dl); at an A 1c of 8%, between 8 and 11 mmol/l (144 and 198 mg/dl); and at an A 1c of 9%, between 10.5 and 13.5 mmol/l (189 and 243 mg/dl), again suggesting that factors other than glycaemia may play a role in haemoglobin glycation [25] . In a similar analysis of a CGM database of children with type 1 diabetes, with A 1c measured using an assay referable to the DCCT standard, at an A 1c of 7%, mean glucose ranged from 7.6-10.5 mmol/l (138-189 mg/dl) [26] .
Another line of evidence suggesting that A 1c may not predict glycaemia similarly across populations comes from comparison among various groups of persons without diabetes. The 'glycation gap' quantifies the relationship between the glycation of intracellular haemoglobin and that of extracellular plasma proteins. The former is additionally influenced by access of glucose to the intra-erythrocyte space, the non-enzymatic glycation rates of haemoglobin, and red blood cell survival. Studies of twins by Cohen et al. have suggested that almost 70% of the glycation gap is heritable and, therefore, genetically pre-determined [27] . In the Diabetes Prevention Program, which involved 3,234 patients with impaired glucose tolerance, the mean A 1c in non-Hispanic whites was 5.78%, whereas the corresponding values in Hispanic, Asian, American-Indian, and AfricanAmerican individuals were 5.93%, 6.00%, 6.12% and 6.18%, respectively, after adjustments for both fasting and postprandial glucose, as well as other demographic and clinical features. These data strongly suggest an important ethnicityrelated difference in the glycation of haemoglobin [28] . In a study comparing obese with non-obese South Asian men with neither hypertension nor diabetes, glycated haemoglobin was higher in the former, showing a correlation with the malondialdehyde level, suggesting that glycation may vary with lipid peroxide levels, perhaps reflecting oxidative stress [29] . Finally, other lines of inquiry have suggested that one-quarter of diabetic patients have an A 1c 1 percentage point higher and that one-sixth have an A 1c 1 percentage point lower than the value that would be predicted from simultaneously measured glycated serum protein concentration [30] .
Based on the above arguments, it seems that although the new advances represented by the IFCC methodology do offer the opportunity to introduce a more accurate approach to A 1c measurement, it would be a mistake to report the results of the new assay in terms such as ADAG. If change must occur (and reasonable arguments can be made to maintain the status quo), the best option might be to introduce the new measurement in its precise units, namely mmol/mol, with an entirely new normative range, also reporting A 1c in DCCT percentage equivalent units for a limited period of time. Although an accompanying intensive educational effort for both clinicians and patients would be necessary, a more complete understanding of the relationship between A 1c and glycaemia could then emerge. Although A 1c should continue to play a major role in diabetes management and should continue to remain the gold standard for groups of diabetic patients in clinical trials, it will undoubtedly be better applied to an individual patient when accompanied by a full understanding of their actual patterns of glucose control. Such patterns may be derived from analysis of glucose meter-derived home glucose patterns. As CGM becomes more readily available, this approach to determination of average glucose concentrations could prove to be particularly robust, and in some cases may be considered more useful than the A 1c measurement itself. Because, however, CGM requires considerably more effort to ascertain, the need for A 1c determination remains certain for the foreseeable future. The ultimate goal will be to develop and validate new approaches to the understanding of glycaemic exposure of persons with diabetes, and, as a result, their underlying risk of micro-and macrovascular complications.
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